常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.15/0.13
|
|
企業價值
1.36B
|
| 資產負債 |
|
每股賬面淨值
-0.21
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
348.97M
|
|
每股收益
0.55
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. |

3.19 
